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Abstract
It is difficult to predict how antibodies will behave when mixed together, even after each has been
independently characterized. Here, we present a statistical mechanical model for the activity of antibody
mixtures that accounts for whether pairs of antibodies bind to distinct or overlapping epitopes. This
model requires measuring n individual antibodies and their n(n−1)2 pairwise interactions to predict the
2n potential combinations. We apply this model to epidermal growth factor receptor (EGFR) antibodies
and find that the activity of antibody mixtures can be predicted without positing synergy at the
molecular level. In addition, we demonstrate how the model can be used in reverse, where straightforward
experiments measuring the activity of antibody mixtures can be used to infer the molecular interactions
between antibodies. Lastly, we generalize this model to analyze engineered multidomain antibodies,
where components of different antibodies are tethered together to form novel amalgams, and characterize
how well it predicts recently designed influenza antibodies.
Author summary
With the rise of new combination antibody therapeutic regimens, it is important to understand how
antibodies work together as well as individually. Here, we investigate the specific case of monoclonal
antibodies targeting a cancer-causing receptor or the influenza virus and develop a statistical mechanical
framework that predicts the effectiveness of a mixture of antibodies. The power of this model lies in its
ability to make a large number of predictions based on a limited amount of data. For example, once
10 antibodies have been individually characterized, our model can predict how any of the 210 = 1024
combinations will behave. This predictive power provides ample opportunities to test our model and
paves the way to expedite the design of future therapeutics.
Introduction
Antibodies can bind with strong affinity and exquisite specificity to a multitude of antigens. Due to their
clinical and commercial success, antibodies are one of the largest and fastest growing classes of therapeutic
drugs [1]. While most therapies currently use monoclonal antibodies (mAbs), mounting evidence suggests
that mixtures of antibodies can behave in fundamentally different ways [2]. There is ample precedent for
the idea that combinations of therapeutics can be extremely powerful—for instance, during the past 50
years the monumental triumphs of combination anti-retroviral therapy and chemotherapy cocktails have
provided unprecedented control over HIV and multiple types of cancer [3,4], and in many cases no single
drug has emerged with comparable effects. However, it is difficult to predict how antibody mixtures
will behave relative to their constitutive parts. Often, the vast number of potential combinations is
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prohibitively large to systematically test, since both the composition of the mixture and the relative
concentration of each component can influence its efficacy [5].
Here, we develop a statistical mechanical model that bridges the gap between how an antibody
operates on its own and how it behaves in concert. Specifically, each antibody is characterized by its
binding affinity and potency, while its interaction with other antibodies is described by whether its
epitope is distinct from or overlaps with theirs. This information enables us to translate the molecular
details of how each antibody acts individually into the macroscopic readout of a system’s activity in the
presence of an arbitrary mixture.
To test the predictive power of our framework, we apply it to a beautiful recent case study of
inhibitory antibodies against the epidermal growth factor receptor (EGFR), where 10 antibodies were
individually characterized for their ability to inhibit receptor activity and then all possible 2-Ab and
3-Ab mixtures were similarly tested [6]. We demonstrate that our framework can accurately predict the
activity of these mixtures based solely on the behaviors of the ten monoclonal antibody as well as their
epitope mappings.
Lastly, we generalize our model to predict the potency of engineered multidomain antibodies from
their individual components. Specifically, we consider the recent work by Laursen et al. where four
single-domain antibodies were assayed for their ability to neutralize a panel of influenza strains, and
then the potency of constructs comprising 2-4 of these single-domain antibodies were measured [7]. Our
generalized model can once again predict the efficacy of the multidomain constructs based upon their
constitutive components, once a single fit parameter is inferred to quantify the effects of the linker
joining the single-domain antibodies. This enables us to quantitatively ascertain how tethering antibodies
enhances the two key features of potency and breadth that are instrumental for designing novel anti-viral
therapeutics. Notably, our models do not posit complex molecular synergy between antibodies. Our
results therefore show that many antibody mixtures function without synergy, and hence that their
effects can be computationally predicted to expedite future experiments.
Results
Modeling the mechanisms of action for antibody mixtures
Consider a monoclonal antibody that binds to a receptor and inhibits its activity. Two parameters
characterize this inhibition: (1) the dissociation constant KD quantifies an antibody’s binding affinity
(with a smaller value indicating tighter binding) and (2) the potency α relates the activity when an
antibody is bound to the activity in the absence of antibody. A value of α = 1 represents an impotent
antibody that does not affect activity while α = 0 implies that an antibody fully inhibits activity upon
binding. As derived in S1 Text Section A, for an antibody that binds to a single site on a receptor, the
activity at a concentration c of antibody is given by
Fractional Activity =
1 + α cKD
1 + cKD
. (1)
To characterize a mixture of two antibodies, we not only need their individual dissociation constants
and potencies but also require a model for how these antibodies interact. When two antibodies bind to
distinct epitopes, the simplest scenario is that their ability to bind and inhibit activity is independent of
the presence of the other antibody, and hence that their combined potency when simultaneously bound
equals the product of their individual potencies (Fig 1A). Alternatively, if the two antibodies compete
for the same epitope, they cannot both be simultaneously bound (Fig 1B).
We also define the general case of a synergistic interaction where the binding of the first antibody
alters the binding or potency of the second antibody (Fig 1C, purple text). This definition encompasses
cases where the second antibody binds more tightly (K
(2)
D,eff < K
(2)
D ) or more weakly (K
(2)
D,eff > K
(2)
D ) in
the presence of the first antibody, as well as when the potency of the second antibody may increase
(α2,eff > α2) or decrease (α2,eff < α2). This also includes cases where two epitopes slightly overlap and
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Figure 1. Binding modes for a 2-Ab mixture. Two antibodies with concentrations c1 and c2 can
bind (A) independently to different epitopes or (B) competitively to the same epitope. (C) Antibodies
bind synergistically if either the product of binding affinities (K
(j)
D ) or potencies (αj) are altered when
both antibodies bind.
partially inhibit one another’s binding, and the competitive binding model can be viewed as the extreme
limit K
(2)
D,eff →∞ where one antibody infinitely penalizes the binding of the other.
While the synergistic model in Fig 1C has the merit of being highly general, an important feature
of the independent and competitive models (Fig 1A,B) is that they predict all antibody combinations
with few parameters. In both of these latter models, once the K
(j)
D and αj of 10 antibodies are known
(which requires 2 · 10 experiments) and their epitopes are mapped ( 10·92 additional experiments), the
potency of all 210 = 1024 possible mixtures of these antibodies can be predicted without recourse to
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fitting. In contrast, because the synergistic model allows arbitrary interactions between each combination
of antibodies, the behavior of a mixture exhibiting synergy cannot be predicted without actually making
a measurement on that combination to quantify the synergy.
For these reasons, in this work we focus on the two cases of independent or competitive binding and
show how we can combine both models to transform our molecular understanding of each monoclonal
antibody’s action into a prediction of the efficacy of an antibody mixture. Deviations from our predictions
provide a rigorous way to measure antibody synergy by computing
K
(2)
D,eff
K
(2)
D
and
α2,eff
α2
.
To mathematize the independent and competitive binding models, we enumerate the possible binding
states and compute their relative Boltzmann weights. The fractional activity of each state equals the
product of its relative probability and relative activity divided by the sum of all relative probabilities
for normalization (see S1 Text Section A). When two antibodies bind independently as in Fig 1A, this
factors into the form
Fractional Activity(distinct epitopes) =
1 + α1 c1K(1)D
1 + c1
K
(1)
D
1 + α2 c2K(2)D
1 + c2
K
(2)
D
 . (2)
If these two antibodies compete for the same epitope as in Fig 1B, the activity becomes
Fractional Activity(overlapping epitopes) =
1 + α1
c1
K
(1)
D
+ α2
c2
K
(2)
D
1 + c1
K
(1)
D
+ c2
K
(2)
D
. (3)
These equations are readily extended to mixtures with three or more antibodies (see S1 Text Section A).
Antibody mixtures against EGFR are well characterized using independent
and competitive binding models
To test the predictive power of the independent and competitive binding models, we applied them to
published experiments on the epidermal growth factor receptor (EGFR) where ten monoclonal antibodies
were individually characterized and then the activity of all 165 possible 2-Ab and 3-Ab mixtures was
measured [6]. We first use each monoclonal antibody’s response to infer its dissociation constant KD
and potency α. We then utilize surface plasmon resonance (SPR) measurements to determine which
pairs of antibodies bind independently and which compete for the same epitope. These data enable us to
use the above framework and predict EGFR activity in the presence of any mixture.
EGFR is a transmembrane protein that activates in the presence of epidermal growth factors. Upon
ligand binding, the receptor’s intracellular tyrosine kinase domain autophosphorylates which leads to
downstream signaling cascades central to cell migration and proliferation. Overexpression of EGFR has
been linked to a number of cancers, and decreasing EGFR activity in such tumors by sterically occluding
ligand binding has reduced the rate of cancer proliferation [6].
Koefoed et al. investigated how a panel of ten monoclonal antibodies inhibit EGFR activity in the
human cell line A431NS [6]. They then measured how 1:1 mixtures of two antibodies or 1:1:1 mixtures
of three antibodies affect EGFR activity. All measurement were carried out at a total concentration of
2 µgmL , implying that each antibody was half as dilute in the 2-Ab mixtures and one-third as dilute in the
3-Ab mixtures relative to the monoclonal antibody measurement.
The 45 possible 2-Ab mixtures (35 binding to distinct epitopes; 10 binding to overlapping epitopes)
and the 120 possible 3-Ab mixtures (50 binding to distinct epitopes; 70 binding to overlapping epitopes)
were assayed for their ability to inhibit EGFR activity. Fig 2A shows the experimental measurements for
mixtures of two antibodies, with the monoclonal antibody measurements shown on the diagonal, the
measured activity of 2-Ab mixtures shown on the bottom-left and the predicted activity on the top-right.
Each antibody is labeled with its binding epitopes inferred through SPR [6], so that antibodies binding
to overlapping epitopes are predicted using Eq (3) (pairs within the dashed gray boxes) while mixtures
binding to distinct epitopes use Eq (2).
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Figure 2. Predicting how antibody mixtures affect the epidermal growth factor receptor
(EGFR). (A) The fractional activity of EGFR in the presence of monoclonal antibodies (diagonal)
together with the measured (bottom-left) and predicted (top-right) activity of all 2-Ab combinations.
The dashed gray boxes enclose antibody pairs that compete for the same epitope while all other pairs
bind independently. (B) The predicted versus measured fractional activity for all 2-Ab and 3-Ab
mixtures using the same epitope mapping as in Panel A inferred by SPR. Without the epitope map, the
activity of the mixtures could alternately be predicted by assuming that all antibodies either (C) bind
independently or (D) compete for the same epitope; in either case, the resulting predictions fall further
from the diagonal line, indicating poorer predictive power.
For example, antibodies #1 and #4 bind to distinct epitopes (III/C and III/B, respectively). Hence,
the predicted activity of their mixture (0.50) very nearly equals the product of their individual activity
(0.65× 0.75 = 0.49), with the slight deviation arising because each antibody concentration was halved in
the mixture (c1 = c2 = 1
µg
mL for the 2-Ab mixture characterized by Eq (2), whereas the individual mAbs
were measured at c = 2 µgmL using Eq (1)). The predicted activity roughly approximates the measured
value 0.43 of the mixture.
On the other hand, antibodies #1 and #2 bind to the same epitope (III/C), and hence their
predicted combined activity (0.67) lies between their individual activities (0.65 and 0.69) since both
antibodies compete for the same site. The measured activity of the mixture (0.65) closely matches the
prediction of the overlapping epitope model, but is very different than the prediction of 0.45 made by
the distinct-binding model.
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Fig 2B shows the measured EGFR activity in the presence of all 2-Ab and 3-Ab mixtures is highly
correlated with the predicted activity (R2 = 0.90) Notably, the predictions are made solely from the
monoclonal antibody data and epitope measurements, and do not involve any fitting of the 2-Ab or
3-Ab measurements. The strong correlation between the predicted and measured activities suggests that
EGFR antibody mixtures can be characterized with minimal synergistic effects in either their binding or
effector functions. If we did not have the epitope mapping through SPR and assumed that all antibodies
bound to distinct epitopes (Fig 2C, R2 = 0.85) or competed for the same epitope (Fig 2D, R2 = 0.86),
the resulting predictions are slightly more scattered from the diagonal, demonstrating that properly
acknowledging which pairs of antibodies vie for the same epitope boosts the predictive power of the
model.
That said, the predictions incorporating the SPR mapping display a consistent bias towards having a
slightly lower measured than predicted activity, suggesting that several pairs of antibody enhance one
another’s binding affinity or potency. To quantify this, if we recharacterize the activity from the 2-Ab
mixtures to a synergistic model where each α2,eff is fit to exactly match the data, we find an average
value of
α2,eff
α2
= 0.9, showing that when pairs of antibodies are simultaneously bound they typically
boost their collective inhibitory activity by ∼10%.
Differentiating distinct versus overlapping epitopes using antibody mixtures
In the previous section, we used SPR measurements to quantify which antibodies compete for overlapping
epitopes, thereby permitting us to translate the molecular knowledge of antibody interactions into a
macroscopic quantity of interest, namely, the activity of EGFR. In this section, we do the reverse and
utilize activity measurements to categorize which subsets of antibodies bind to overlapping epitopes. This
method can be applied to model antibody mixtures in other biological systems where SPR measurements
are not readily available.
For the remainder of this section, we ignore the known epitope mappings discerned by Koefoed et
al. and consider what mapping best characterizes the data. For example, given the individual activities
of antibody #1 (0.65) and #2 (0.69), the predicted activity of their combination (at the concentration
of 1 µgmL for each antibody dictated by the experiments) would be 0.45 if they bind to distinct epitopes
and 0.67 if they bind to overlapping epitopes. Since the measured activity of this mixture was 0.65,
it suggests the latter option. We note that such analysis will work best for potent antibodies (whose
individual activity is far from 1), since only in this regime will the predictions of the distinct versus
overlapping models be significantly different. Therefore, the activity measurements of each individual
antibody would optimally be carried out at saturating concentrations (where Eq (1) is as far from 1 as
possible).
Proceeding to the other antibodies, we characterize each pair according to whichever model prediction
lies closer to the experimental measurement. To account for experimental error, we left an antibody pair
uncategorized if the two model predictions were too close to one another (within 4σ = 0.16 where σ is
the SEM of the measurements) or if the experimental measurement was close (within 1σ) to the average
of the two model predictions (see S1 Text Section B).
Fig 3A shows how this analysis compares to the experimental measurement inferred by SPR. While
the model predictions are much sparser (with the majority of antibody pairs uncategorized because
the two model predictions were too close to one another), the classifications only disagreed with the
SPR measurements in two cases (claiming that antibodies #7-8 overlap with antibody #10; notice that
antibodies #7-8 have individual activities close to 1, making them difficult to characterize).
Using these classifications, we defined unique EGFR epitopes by grouping together any antibodies
that bind to overlapping epitopes. In this way, we split the ten antibodies into four distinct groups
(antibodies #1-3, #4-5, #6, and #7-10 indicated by the dashed gray rectangles in Fig 3A), enabling
us to distinguish which antibodies bind independently or competitively and hence predict the activity
of the 2-Ab and 3-Ab mixtures. Note that it is not the pairwise classification between two antibodies
that determines whether we apply the distinct or competitive models, but rather these four groupings of
antibody epitopes. For example, although antibodies #7 and #8 are uncategorized through their 2-Ab
mixture, they fall within a single epitope group and hence are considered to bind competitively. Similarly,
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Figure 3. Classifying antibody epitopes as overlapping or distinct. (A) Comparing the
experimentally measured activity to the overlapping or distinct epitope models enables us to
characterize each antibody pair (provided the two models predict sufficiently different activities). (B)
The resulting predictions for the 2-Ab and 3-Ab mixtures have the same predictive power (R2 = 0.90) as
a model that relies on epitope groupings given by SPR measurements (Fig 2B).
antibody #1 and #4 are modeled as binding independently because they belong to two distinct epitope
groups. Antibody #6 is considered to be in its own epitope group since it did not overlap with any other
antibody.
Surprisingly, the results shown in Fig 3B have a coefficient of determination R2 = 0.90 that is on par
with the results obtained using the SPR measurements (Fig 2B). This suggests that there is no loss in
the predictive power of the model when an epitope mapping is inferred through activity measurements.
In summary, whether antibodies bind independently or competitively can be determined either: (1)
directly through pairwise competition experiments or (2) by analyzing the activity of their 2-Ab mixtures
in light of our two models. When this information is combined with the potency and dissociation constant
of each antibody, the activity of an arbitrary mixture can be predicted. The Supplementary Information
contains a Mathematica program that can analyze either form of the pairwise interactions to determine
the epitope grouping. If the characteristics of the individual antibodies are also provided, the program
can predict the activity of any antibody mixtures at any specified ratio of the constituents.
Multidomain antibodies boost breadth and potency via avidity
While the previous sections analyzed combinations of whole, unmodified antibodies, we now extend our
framework to connect with the rising tide of engineering efforts that genetically fuse different antibody
components to construct multi-domain antibodies [8]. Specifically, we focus our attention on recent work
by Laursen et al. who isolated single-domain antibodies from llamas immunized with H2 or H7 influenza
hemagglutinin (HA) [7]. The four single-domain antibodies isolated in this manner included one antibody
that preferentially binds influenza A group 1 strains (AbA1), another that binds influenza A group 2
strains (AbA2), and two antibodies that bind to influenza B strains (Ab
(1)
B and Ab
(2)
B ). Fig 4A,B shows
data from a representative influenza A group 1 strain (blue dot, only bound by the blue AbA1), influenza
A group 2 strain (green dot, only bound by the green AbA2), and influenza B strain (gold dot, bound by
both of the yellow Ab
(1)
B and Ab
(2)
B antibodies).
In the contexts of rapidly evolving pathogens such as influenza, two important characteristics of
antibodies are their potency and breadth. Potency is measured by the inhibitory concentration IC50 at
which 50% of a virus is neutralized, where a smaller IC50 represents a better antibody. Breadth is a
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measure of how many strains are susceptible to an antibody.
In an effort to improve the potency and breadth of their antibodies, Laursen et al. tethered together
different domains using a flexible amino acid linker (right-most columns of Fig 4A,B) and tested them
against a panel of influenza strains. To make contact with these multidomain constructs, consider a
concentration c of the tethered antibody AbA1–AbA2. Relative to the unbound HA state, the AbA1
or AbA2 portions of the antibody will neutralize the virus with relative probability
c
IC50,A1
or cIC50,A2 ,
respectively. Although neutralization is mediated by antibody binding, the two quantities may or may
not be proportional [9–11], and hence we replace dissociation constants with IC50s in our model (see S1
Text Section C).
Laursen et al. determined that their tethered constructs cannot intra-spike crosslink two binding sites
on a single HA trimer, but they can inter-spike crosslink adjacent HA [7]. The linker connecting the
two antibody domains facilitates such crosslinking, since when one domain is bound the other domain
is confined to a smaller volume around its potential binding sites. This effect can be quantified by
stating that the second domain has an effective concentration ceff (Fig 4C, purple), making the relative
probability of the doubly bound state cIC50,A1
ceff
IC50,A2
. Therefore, the fraction of virus neutralized by two
tethered antibody domains is given by
Fraction Neutralized =
c
IC50,A1
+ cIC50,A2 +
c
IC50,A1
ceff
IC50,A2
1 + cIC50,A1 +
c
IC50,A2
+ cIC50,A1
ceff
IC50,A2
. (4)
Note that this equation assumes that influenza virus is fully neutralized at saturating concentrations of
antibody (α = 0 in Eq (1), with Fraction Neutralized analogous to 1− Fractional Activity).
The IC50 of the tethered construct is defined as the concentration c at which half of the virus is
neutralized, which can be solved to yield
IC50,A1–A2 =
IC50,A1 IC50,A2
ceff + IC50,A1 + IC50,A2
, (5)
with an analogous expression holding for the Ab
(1)
B –Ab
(2)
B construct. Using the measured IC50s of
AbA1–AbA2 and Ab
(1)
B –Ab
(2)
B against the various influenza strains, we can infer the value of the single
parameter ceff = 1400 nM (see S1 Text Section C). This result is both physically meaningful and
biologically actionable, as it enables us to predict the IC50 of the tethered multidomain antibodies against
the entire panel of influenza strains. Fig 5A,B compares the resulting predictions to the experimental
measurements, where plot markers linked by horizontal line segments indicate a close match between the
predicted and measured values.
The two tethered antibodies display unique trends that arise from their compositions. Since the
two domains in AbA1–AbA2 bind nearly complementary strains, the tethered construct will increase
breadth (since this multidomain antibodies can now bind to both group 1 and group 2 strains) but
will only marginally improve potency. Mathematically, if AbA1 binds tightly to an influenza A group
1 strain while AbA2 binds weakly to this same strain (IC50,A2 → ∞), their tethered construct has an
IC50,A1–A2 ≈ IC50,A1. Said another way, AbA1–AbA2 should be approximately as potent as a mixture of
the individual antibodies AbA1 and AbA2. Note that since the experiments could not accurately measure
weak binding (> 1000 nM), the predicted IC50 for the multidomain antibodies represents a lower bound.
On the other hand, tethering the two influenza B antibodies yields a marked improvement in
potency over either individual antibody, since both domains can bind to any influenza B strain and
boost neutralization via avidity. The process of engineering a multivalent interaction is reminiscent of
engineered bispecific IgG [8], and adding additional domains could yield further enhancement in potency,
provided that all domains can simultaneously bind.
While the model is able to characterize the majority of tethered antibodies, it also highlights some of
the outliers in the data. For example, the H3N2 strains A/Panama/2007/99 and A/Wisconsin/67/05
were poorly neutralized by either AbA1 or AbA2 (IC50 ≥ 1000 nM), but the tethered construct exhibited
an IC50 = 14 nM and IC50 = 17 nM, respectively, far more potent than the 300 nM lower limit predicted
for both viruses (red circles in Fig 4D and red lines in Fig 5A). Interestingly, Laursen et al. found
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Figure 4. Tethering influenza antibodies increases breadth and potency. (A) The influenza
A antibodies AbA1 and AbA2 were tethered together to form AbA1–AbA2 while (B) two influenza B
antibodies formed Ab
(1)
B –Ab
(2)
B . Representative data shown for an influenza A group 1 (blue), influenza
A group 2 (green), and influenza B (gold) strains. Strong potency is marked by a small IC50 while large
breadth implies that multiple strains are controlled by an antibody. (C) Representative states of HA
and their corresponding Boltzmann weights for multidomain antibodies, where crosslinking between
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of the potency of all multidomain antibodies versus their measured values. The red points denote two
outlier influenza strains discussed in the text that are not neutralized by AbA1 or AbA2 individually but
are highly neutralized by their combination.
that mixing the individual, untethered antibodies AbA1 and AbA2 also resulted in shockingly poor
neutralization (IC50 ≥ 1000 nM), suggesting that the tether is responsible for the increase in potency [7].
From the vantage of our quantitative model, this outlier cries out for further investigation.
To further boost neutralization, Laursen et al. created two additional constructs that combined all
four antibody domains, the first being the linear chain (AbA1–AbA2–Ab
(1)
B –Ab
(2)
B ). Since the influenza
A antibodies do not bind the influenza B strains (and vise versa), this construct should have the same
IC50 as AbA1–AbA2 for the influenza A strains and as Ab
(1)
B –Ab
(2)
B for the influenza B strains, as was
found experimentally (compare the Predicted columns in Fig 5A-C). For example, the two H3N2 strains
(A/Panama/2007/99 and A/Wisconsin/67/05) were again found to have measured IC50s (15 nM and
23 nM) far smaller than their predicted lower bound of 300 nM (red squares in Fig 4D, red lines in
Fig 5C).
A second construct containing all four antibody domains attached two copies of AbA1–AbA2–Ab
(1)
B –Ab
(2)
B
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Figure 5. Neutralization of multidomain antibodies. (A,B) The potency of the 2-Ab constructs
and their constitutive antibodies against a panel of influenza strains. AbA1 primarily binds influenza A
group 1 (blue), AbA2 to influenza A group 2 (green), and the two AbB antibodies to influenza B strains
(gold). (C) All four antibodies were tethered to form the linear chain AbA1–AbA2–Ab
(1)
B –Ab
(2)
B and (D)
two copies of this chain were placed on an IgG backbone. The model suggests that the two arms of the
IgG are not capable of simultaneously binding a virion. Red lines indicate two outlier influenza strains
discussed in the text that are not neutralized by AbA1 or AbA2 individually but are highly neutralized
by their combination. Data was digitized from Figs 1 and 3 of Ref [7].
through an IgG backbone (Fig 5D). Since the identical domains in both arms of this construct should
be able to simultaneously bind, the new antibody should markedly boost potency through avidity.
Surprisingly, the neutralization of this final construct was well characterized as half the IC50 of an
individual AbA1–AbA2–Ab
(1)
B –Ab
(2)
B , suggesting that there was no noticeable avidity and that the increase
in neutralization only arose from having twice as many antibody domains. As above, this intriguing
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result presents an opportunity to both quantitatively check experimental results and to advocate for
future studies in potentially highly promising directions. In this particular instance, it suggests that the
IgG backbone used did not permit simultaneous binding of both arms. If a different multivalent scaffold
(perhaps with greater flexibility or with longer linkers) enabled bivalent binding of both arms, it could
potentially increase the neutralization of this construct by 100-fold as seen in the influenza B constructs.
Discussion
In this work, we developed a statistical mechanical model that predicts the collective efficacy of an
antibody mixture whose constituents are assumed to bind to a single site on a receptor. Each antibody
is first individually characterized by its ability to bind the receptor (through its dissociation constant
KD) and inhibit activity (via its potency α) as per Eq (1). Importantly, this implies that the activity
of each monoclonal antibody must be measured at a minimum of two concentrations in order to infer
both parameters, and additional measurements would further refine these parameter values and the
corresponding model predictions.
After each antibody is individually characterized, the activity of a combination of antibodies will
depend upon whether they bind independently to distinct epitopes or compete for overlapping epitopes.
Theoretical models often assume for simplicity that all antibodies bind independently, and in the contexts
where this constraint can be experimentally imposed such models can accurately predict the effectiveness
of antibody mixtures [12]. Yet when the antibody epitopes are unknown or when a large number
of antibodies are combined, it is likely that some subset of antibodies will compete with each other
while others will bind independently, which will give rise to a markedly different response. Our model
generalized these previous results to account for antibody mixtures where arbitrary subsets can bind
independently or competitively (Eqs (2) and (3), S1 Text Section A).
We showed that in the context of the EGFR receptor, where every pairwise interaction was measured
using surface plasmon resonance, our model is better able to predict the efficacy of all 2-Ab and 3-Ab
mixtures than a model that assumes all antibodies bind independently or competitively (Fig 2). This
suggest that mixtures of antibodies do not exhibit large synergistic effects. More generally, similar
models in the contexts of anti-cancer drug cocktails and anti-HIV antibody mixtures also found that the
majority of cases that were described as synergistic could instead be characterized by an independent
binding model [12, 13]. This raises the possibility that synergy is more the exception then the norm, and
hence that simple models can computationally explore the full design space of antibody combinations.
While it is often straightforward to measure the efficacy of n individual antibodies, it is more
challenging to quantify all n(n+1)2 pairwise interactions and determine which antibodies bind independently
and which compete for an overlapping epitope. We demonstrated that after each antibody is individually
characterized, our model can be applied in reverse by using the activity of 2-Ab mixtures to classify whether
antibodies compete or bind independently (Fig 3). Surprisingly, while the resulting categorizations were
much sparser than the direct SPR measurements, the classifications produced by this method predicted
the efficacy of antibody combinations with an R2 = 0.90, comparable to the predictions made using the
complete SPR results (Fig 2B). This suggests that key features of how antibodies interact on a molecular
level can be indirectly inferred from simple activity measurements of antibody combinations.
Modern bioengineering has opened up a new avenue of mixing antibodies by genetically fusing different
components to construct multi-domain antibodies [8]. Such antibodies can harness multivalent interactions
to greatly increase binding avidity by over 100x (e.g. comparing the IC50s of the A/Wisconsin/67/05
and B/Harbin/7/94 strains of the 4-fused domains on an IgG backbone in Fig 5D to the corresponding
IC50s for the individual antibody domains in Panels A and B). For such constructs, the composition of
the linker can heavily influence the ability to multivalently bind and neutralize a virus [11, 14], although
Laursen et al. surprisingly found little variation when they modified the length of their amino acid linker
(see Table S11 in Ref [7]). Another curious feature of their system was that placing their linear 4-domain
antibody (Fig 5C) on an IgG backbone (Fig 5D) only resulted in a 2x decrease in IC50, suggesting that
the two “arms” of the IgG could not simultaneously bind. We would expect that a different backbone
that allows both arms to simultaneously bind would markedly increase the neutralization potency of this
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construct. In this way, quantitatively modeling these multidomain antibodies can guide experimental
efforts to design more potent constructs.
To close, we mention that two possible avenues of future work. First, although our model classifies
antibody epitopes as either distinct or overlapping, SPR measurements indicate that there is a continuum
of possible interactions. It would be fascinating to translate this more nuanced level of interaction into
more precise dissociation constants when two antibodies are bound. Second, while our model focused
on mixtures of antibodies, it can be applied equally well to small molecule drugs where the number
of distinct combinations may be prohibitively large to measure experimentally but straightforward to
explore computationally.
Methods
The coefficient of determination used to quantify how well the theoretical predictions matched the
experimental measurements (Fig 2B-D, Fig 3B, Fig 4D) was calculated using
R2 = 1−
∑n
j=1
(
y
(j)
measured − y(j)predicted
)2
∑n
j=1
(
y
(j)
data
)2 (6)
where ymeasured and ypredicted represent a vector of the measured and predicted activities for the n
mixtures analyzed. In Fig 4D, we computed the R2 of log10(activity) to prevent the largest activities
from dominating the result (since the IC50 values span multiple decades).
Data from the EGFR antibody mixtures was obtained by digitizing Ref [6] Fig S1 using Web-
PlotDigitizer [15]. Data for the influenza multidomain antibodies was obtained from the authors of
Ref [7].
The EGFR antibody epitopes experimentally characterized through SPR (Fig 3A, bottom-left) were
categorized as overlapping if the average of the two antibody measurements (with preincubation by
either antibody) were > 50 and as distinct if the average was < 50.
The original nomenclature for the antibodies used in Koefoed et al. and Laursen et al. are given in S1
Text Table S1.
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A Characterizing Antibodies Targeting the Receptor Tyrosine
Kinase EGFR
A.1 Monoclonal Antibody Binding to a Receptor
In this section, we explain the states and weights notation used to develop the equilibrium statistical
mechanical models used in this work. As a focus, we consider the case of an antibody binding to a single
site on a receptor as shown in Fig S1A. We assume that the concentration of the antibody far exceeds
that of the receptor, so that one binding event will not noticeably affect the concentration c of free
antibody.
The receptor can exist in two states where it is either unbound or bound to the antibody, where
the relative probability of the bound state compared to the unbound state equals cKD , where KD is the
dissociation constant of the receptor-antibody binding [16]. The (normalized) probability of each state is
given by its relative weight divided by the sum of the relative weights of all states. For example, the
probability that the receptor is bound to the antibody is shown to be the standard
c
KD
1+ cKD
sigmoidal
response. As expected, the receptor will always be unbound in the absence of antibody (c = 0), while
the receptor will always be bound at saturating concentrations of antibody (c→∞).
Each receptor state also has a relative activity (i.e. the activity of the receptor when it is in this
state). In the context of EGFR, where the fractional activity is measured relative to the receptor in
the absence of antibody, the relative activity of the unbound state is by definition equal to 1. As in the
main text, we define the activity of the bound receptor to be α, where α = 0 implies that the receptor is
completely inactive when the antibody is bound and α = 1 represents the opposite limit where antibody
binding does not inhibit the receptor’s activity. A value of 0 < α < 1 represents an antibody that
partially inhibits activity upon binding.
The activity of the receptor in each state is given by the product of its relative activity and the
normalized probability of that state. Lastly, the average activity of the receptor is given by the sum of
its activity in each state,
Activity =
1 + α cKD
1 + cKD
. (S1)
B
A Receptor
State
All receptor
states
Relative
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1
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Activity
1
Weighted
Activity
Figure S1. A statistical mechanical model of an antibody binding to a receptor. (A) The
relative probability and relative activity of each receptor state enable us to derive the average activity of
the receptor. (B) This method gives the same result of the dynamics model shown by the multiple rates,
provided that the system is in steady state.
S1
As a quick aside, we note out that all the models considered in this work analyze binding reactions
that quickly reach steady, and hence the equilibrium model derived above will should accurately describe
such systems. Eq (S1) can also be derived by considering the dynamics of the system shown in the rates
diagram Fig S1B. The unbound receptor (R) will switch to the bound state (R–Ab) at the rate ckon
(recall that c is the concentration of antibody) and subsequently unbind at a rate koff. Hence, the system
is governed by the two differential equations
d[R]
dt
= koff[R–Ab]− ckon[R] (S2)
d[R–Ab]
dt
= ckon[R]− koff[R–Ab]. (S3)
Since the total amount of receptor [Rtot] = [R] + [R–Ab] is fixed, these two equations are equivalent,
and either one can be solved to yield the dynamics of the system, namely,
[R] = c1e
−(koff+ckon)t + [Rtot]
koff
koff + ckon
. (S4)
c1 is fixed by the initial concentration of free receptor [R] at t = 0, but regardless of its value, we see
that the exponential term will shrink to zero at a time scale of 1koff+ckon , after which the system will be
in steady state with [R] = [Rtot]
koff
koff+ckon
. Defining the dissociation constant KD ≡ koffkon , the probability
that any receptor will be unbound in steady state is given by
[R]
[Rtot]
=
1
1 + cKD
(S5)
as found in Fig S1A.
To close, we note that antibodies typically have a KD = 10
−12–10−8 M, and assuming a diffusion-
limited on rate kon = 10
8–10−9 1M·s , this implies that koff = 10
−3–101 1s . Therefore, an upper bound
(in the limit of little antibody) for the time scale it takes for such a system to reach steady state is
10−1–103 s, which is the time before experimental measurements should be conducted. Since antibodies
are typically preincubated for even longer periods during experiments, an equilibrium model should be
valid in all of the case studies we consider in this work.
A.2 The Fractional Activity of 3-Ab Mixtures
As described in the main text, the fractional activity of 2-Ab mixtures is given by Eq 2 if the two
antibodies bind to distinct epitopes and Eq 3 if they bind to overlapping epitopes. These equations are
straightforward to extend to mixtures with multiple antibodies by drawing all of the statistical weights
and Boltzmann weights for the mixture (analogous to Fig 1) and then computing the fractional activity
as per Section A.1.
For example, a mixture of three antibodies all binding to distinct epitopes would give rise to
Fractional Activity(1,2,3 distinct epitopes) =
1 + α1 c1K(1)D
1 + c1
K
(1)
D
1 + α2 c2K(2)D
1 + c2
K
(2)
D
1 + α3 c3K(3)D
1 + c3
K
(3)
D
 . (S6)
If antibodies 1 and 2 bind to an overlapping epitope but antibody 3 binds to a distinct epitope, then
Fractional Activity(1,2 overlapping epitopes; 3 distinct epitope) =
1 + α1 c1K(1)D + α2 c2K(2)D
1 + c1
K
(1)
D
+ c2
K
(2)
D
1 + α3 c3K(3)D
1 + c3
K
(3)
D
 .
(S7)
If all three antibodies binds to overlapping epitopes, the fractional activity becomes
Fractional Activity(1,2 overlapping epitopes; 3 distinct epitope) =
1 + α1
c1
K
(1)
D
+ α2
c2
K
(2)
D
+ α3
c3
K
(3)
D
1 + c1
K
(1)
D
+ c2
K
(2)
D
+ c3
K
(3)
D
. (S8)
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A.3 Characterizing Ten EGFR Monoclonal Antibodies from Koefoed 2011
Koefoed et al. investigated how a panel of ten monoclonal antibodies inhibit EGFR by measuring the
protein’s activity at multiple antibody concentrations in the human cell line HN5 [6]. By fitting these
titration curves to Eq 1, we can infer the dissociation constant KD between each antibody and EGFR
as well as the potency α of each antibody in the HN5 cell line (Fig S2A,B). For each curve, the KD
corresponds to the midpoint of the curve (halfway between its minimum and maximum activity values)
while α represents the activity at saturating antibody concentration.
Koefoed et al. found that the majority (7/10) of these antibodies reduced EGFR activity below 20%
at saturating concentrations, and since mixtures of antibodies would likely further decrease activity
their potency would be difficult to accurately measure. To that end, Koefoed et al. switched to the
A431NS cell line that is partially resistant to EGFR antibodiess where they remeasured EGFR activity
for all ten monoclonal antibodies as well as mixtures of two or three Abs (with 1:1 and 1:1:1 ratios,
respectively). Each measurement was performed at a mixture concentration of 2 µgmL , implying that each
antibody was half as dilute in the 2-Ab mixtures and one-third as dilute in the 3-Ab mixtures relative to
the monoclonal antibody measurement.
We assume that the antibody-EGFR binding interaction is identical in the A431NS cell line, and
hence that these same KD parameters characterizes these antibodies in that cell line. Hence, by using
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Figure S2. Inferring the model parameters for the 10 monoclonal antibodies in Koefoed
2011. (A) Activity of EGFR in the presence of ten antibodies in the HN5 cell line. (B) The inferred
dissociation constant (KD) and fractional activity in the presence of saturating antibody (α) in each cell
line. (C) Fractional EGFR activity in the presence of 2 µgmL of each antibody in the A431NS cell line.
Data reproduced from Ref [6] Figure 2B,C.
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the additional measurement of each antibody’s potency at 2 µgmL in the A431NS cell line (Fig S2C), we can
infer the potency α of each antibody in the A431NS cell line (Fig S2B). These parameters are sufficient
to predict how any mixture (at any concentration and ratio) will behave in the HN5 and A431NS cell
lines. Note that all data presented in the main text correspond to the A431NS cell line.
A.4 Comparing the HN5 and A431NS Cell Lines from Koefoed 2011
Koefoed et al. measured the potency of 176 mixtures in the A431NS cell line but only 55 mixtures in the
HN5 cell line. Fig S3 extends our analysis to both the A431NS and HN5 cell lines. While the majority of
mixtures have very little predicted and measured activity (. 0.2), approximately 13 outliers fall outside
this range and appear to be poorly predicted.
While the coefficient of determination R2 = 0.61 is significantly lower for this cell line, we note that:
(1) there are far fewer data points in this cell line and (2) that our R2 definition places more importance
on points with larger predicted or measured fractional activity, and hence these few outliers have a
disproportionate effect. That said, it remains unknown whether with more data our model would be as
successful in the HN5 cell line. Another open question is why some antibody mixtures had inhibitory
effects in one cell line but exacerbating effects in the other (e.g. the mixture of Ab3 + Ab10 resulted in
1.22 fractional activity of EGFR in the A431NS cell line but 0.19 fractional activity in the HN5 cell line).
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Figure S3. Predicting the potency of antibody mixtures on EGFR in different cell lines.
Our model predictions versus experimental measurements for EGFR activity in the (A) A431NS and (B)
HN5 cell lines.
A.5 Separating the 2-Ab and 3-Ab Predictions for EGFR Antibody Mix-
tures
Fig S4 separates the 2-Ab and 3-Ab mixture predictions from the three models in Fig 2. More specifically,
Panels A and B of Fig S4 show the predictions for combinations of two and three antibodies using
the epitope mappings produced by SPR (see captions on the diagonal of Fig 2A; there are four EGFR
epitopes bound by antibodies #1-3, #4, #5-6, and #7-10, respectively).
Without this SPR data, we could have alternately assumed that antibodies all bind independently
(Fig S4C,D) or that all antibodies vie for the same epitope (Fig S4E,F). Either of these models generate
slightly worse predictions, as exhibited by their lower coefficients of determination R2.
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Figure S4. Separate predictions for 2-Ab and 3-Ab mixtures. (A,B) Predictions using the
epitope mappings produced using SPR. (C,D) Predictions assuming that all antibodies bind
independently. (E,F) Predictions assuming that all antibodies bind competitively.
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A.6 Original Antibody Nomenclature
Table S1 shows the antibodies considered in this work were named in the original works of Refs. [6]
and [7]. In our work, we indexed the EGFR antibodies by their potency in the A431NS cell line and
labeled the influenza antibodies by the viral group that they most effectively neutralized.
Koefoed 2011 Antibody Nomenclature Laursen 2018 Antibody Nomenclature
.....This Work..... Original Work .....This Work..... Original Work
Ab1 1565 AbA1 SD38
Ab2 1320 AbA2 SD36
Ab3 1024 Ab
(1)
B SD83
Ab4 992 Ab
(2)
B SD84
Ab5 1277
Ab6 1030
Ab7 1284
Ab8 1347
Ab9 1260
Ab10 1261
Table S1. Matching the antibody nomenclature used in this work with the names in the
original manuscript.
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B Characterizing Distinct versus Overlapping EGFR Epitopes
In this section, we describe in more detail how we can use activity data from the 2-Ab mixtures to classify
which subsets of antibodies bind to the same epitopes. A basic classification scheme would categorize
two antibodies as binding to distinct epitopes if Eq 2 predicted their mixture’s activity better than Eq 3;
otherwise, the two antibodies would be categorized as binding to overlapping epitopes.
However, this simple classification scheme does not account for the uncertainty that arises from
experimental noise. As an extreme case, if the activities of a mixtures are measured at extremely small
concentrations, then the fractional activity will be ≈ 1 for all mixtures (as will be the predictions from
both the distinct and overlapping models), and this classification scheme would only be fitting the noise.
Hence, it is best to measure the activity of each mixture at saturating antibody concentrations where
the signal-to-noise of the system will be greatest.
We determined from Koefoed et al. (Figure S1) that the standard error of the mean (SEM) of
their activity measurements was σ = 0.04, and we proceed to incorporate this uncertainty into our
categorization scheme using a simple threshold model. More specifically, we add two components to
the classification scheme: (1) As shown in Fig S5A, activity measurements that fall within σ of the
midpoint of the two model predictions are left unclassified, since experimental noise could easily lead to
such points being incorrectly classified. (2) If the two model predictions lie sufficiently close (within 4σ)
to one another, then the uncertainty (from both the measurement and the model predictions) make it
difficult to distinguish between the two models with certainty.
As mentioned above, for potent antibodies that are measured at saturating concentrations, the
difference between the independent and overlapping binding models will be large, making it easier to
definitively classify antibody epitopes. Koefoed et al. measured their 2-Ab combinations at a total
concentration of 2 µgmL (and hence 1
µg
mL for each antibody), and Fig S2A suggest that while this is close
to saturating concentration for the majority of antibodies, increasing the concentration by 10x may have
allowed more pairs of antibodies to be definitively categorized.
A
Fractional Activity
Independent Binding
Model Prediction
Unclassified
Region
Overlapping Binding
Model Prediction
σσ
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Fractional Activity
>4σ Separation
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Figure S5. Accounting for uncertainty in the classification scheme. (A) 2-Ab combinations
whose activity falls within σ of the midpoint between the two model predictions will be labeled as
“unclassified,” since the difference in distance from the measurement to either prediction is less than the
experimental error. (B) In addition, when the two model predictions are less than 4σ different, any
measurement is labeled as “unclassified” because measurement error could result in overlap with both
model predictions.
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C Characterizing Multidomain Antibodies
C.1 Relating Influenza Neutralization to Binding
In this section, we discuss how the microscopic dissociation constants of two tethered antibodies (shown
in Fig 4C) relate to influenza viral neutralization. We begin by considering a single antibody with an
effective dissociation constant K
(1)
D that quantifies its avidity to the virus [17]. The probability that this
antibody at concentration c will be bound to a virion is given by
pbound =
c
K
(1)
D
1 + c
K
(1)
D
. (S9)
For influenza virus with N ≈ 400 hemagglutinin (HA) trimers, the number of bound trimers is given by
Nbound = Npbound.
The relationship between viral binding and neutralization remain unclear [18]. It has been suggested
that ∼ 50 HA trimers are required to infect a cell [17]. However, an IgG bound to one trimer may
sterically preclude neighboring HA from binding. It has been proposed that neutralization is a sigmoidal
function of neutralization (see Figure S1 of Ref [10]),
Fraction Neutralized =
Nh +Nh50
Nh
(Npbound)
h
(Npbound)
h
+Nh50
, (S10)
where N50 is the number of bound trimers required to reduce infectivity to 50%, h is a Hill coefficient,
and the prefactor assures that the fraction neutralized ranges from 0 (in the absence of antibody) to 1
(in the presence of saturating antibody).
In the absence of data for our influenza strain of interest, we will assume h = 1 in the following
analysis. This enables us to rewrite Eq (S10) as
Fraction Neutralized =
c
IC
(1)
50
1 + c
IC
(1)
50
, (S11)
where we have defined the inhibitory concentration of antibody at which 50% of the virus is neutralized
IC
(1)
50 =
N50
N +N50
K
(1)
D . (S12)
For example, if the virus is 50% neutralized when N50 = 100 trimers are bound, the midpoint of a viral
neutralization curve would occur at roughly 1/5 the antibody concentration required to bind 50% of the
trimers, as has been observed for some influenza antibodies (see Figure 2 of Ref [9]).
We now consider the tethered two-domain antibody shown in Fig 4C. Denote the antibody concen-
tration as c, the effective dissociation constants of its two domains as K
(1)
D and K
(2)
D , and the effective
concentration when both domains simultaneously bind as c˜eff (which we will shortly relate to the ceff in
the antibody neutralization given in Eq 4). The probability that this antibody is bound to a virion is
given by
pbound =
c
K
(1)
D
+ c
K
(2)
D
+ c
K
(1)
D
c˜eff
K
(1)
D
1 + c
K
(1)
D
. (S13)
As above, we assume that neutralization is related to the binding probability through Eq (S10) with
Hill coefficient h = 1, which upon substituting Eq (S13) yields
Fraction Neutralized =
c
IC50,A1
+ cIC50,A2 +
c
IC50,A1
ceff
IC50,A2
1 + cIC50,A1 +
c
IC50,A2
+ cIC50,A1
ceff
IC50,A2
(S14)
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where we have defined the IC50s of both antibodies using Eq (S12) as well as the rescaled effective
concentration
ceff =
N50
N +N50
c˜eff. (S15)
Therefore, in the case where h = 1 the functional form of neutralization (Eq (S14)) is identical to the
probability that an HA trimer is bound (Eq (S13)), with the dissociation constants and the effective
concentration rescaled by N50N+N50 .
To put these results into perspective, we note that many viruses are covered in spikes (analogous
to influenza HA) that enable them to bind and fuse to their target cells [18], and hence the sigmoidal
dependence between viral binding and neutralization is likely widely applicable. However, HIV is a clear
exception, since each virion has an average of 14 envelope spikes [19]. In that context, neutralization is
roughly proportional to the number of bound spikes so that IC50 ≈ KD [20].
C.2 Assuming Different Antibody Constructs have Distinct Effective Con-
centrations
In the main text, we quantified the boost in avidity from tethering two antibodies using the effective
concentration ceff = 1400 nM by using least-squares regression to minimize the (log) predicted IC50 for
each tethered construct binding to all strains. This effective concentration depends on the distance
between binding sites on a virion, and hence the tethered AbA1–AbA2 construct may have a different
ceff when binding to influenza A group 1 and group 2 strains, and Ab
(1)
B –Ab
(2)
B may have yet another
effective concentration when binding to the influenza B strains.
Fig S6 shows the best-fit ceff for each of these cases. While this plot suggests that there are differences
between each tethered antibody and influenza strain, we note that there is very limited data to infer
such values (e.g., there are 7, 7, and 5 data points in the influenza A1, A2, and B groups, respectively;
note that we ignore the H3N2 outlier strains A/Panama/2007/99 and A/Wisconsin/67/05 discussed
in the main text). That said, incorporating this fine-grained level of modeling could further boost the
accuracy of modeling efforts and is worth pursuing as more data is gathered.
Finally, we mention that Laursen et al. measured the efficacy of AbA1–AbA2 with different linkers of
length 18 amino acids (∼ 63A˚), 38 amino acids (∼ 133A˚), and 60 amino acids (∼ 210A˚) against the four
influenza strains H1N1 A/California/07/09, H1N1 A/Puerto Rico/8/34-MA, H5N1 A/Vietnam/1194/04,
and H3N2 A/Wisconsin/67/05 (see Ref [7] Table S11). They found very little difference between the IC50
of each construct, which might naively suggest that the length of the linker does not matter. However,
since these four strains were all negligibly inhibited by AbA2 (IC50 ≥ 1000 nM; see Fig 5A), this domain
cannot meaningfully contribute to bivalent binding, so that AbA1–AbA2 would be expected to be as
potent as AbA1 irrespective of linker length. On the other hand, the length of the linker should matter
when both Abs in a multidomain antibody can bind, as is the case for AbA1–AbA2 binding to the three
influenza A group 2 strains with IC50 < 1000 nM and for Ab
(1)
B –Ab
(2)
B binding to the five influenza B
strains.
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Figure S6. Inferring ceff between every tethered construct binding to each group of
influenza virus. The best-fit effective concentration of AbA1–AbA2 against the influenza A group 1
and group 2 strains, together with the effective concentration of Ab
(1)
B –Ab
(2)
B binding to influenza B.
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